Adaptive radiotherapy for lung cancer treatment
Online-adaptive Radiotherapy in Lung Cancer
University Hospital, Essen · NCT06222190
This study tests a new way of giving radiation therapy for lung cancer that adjusts the treatment plan each day to better target the tumor and protect healthy tissue.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Essen (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Essen, NRW) |
| Trial ID | NCT06222190 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with lung carcinoma undergoing online-adaptive radiotherapy (ART) to adjust treatment plans based on anatomical changes before each radiation session. Using the ETHOS® radiotherapy system, the study aims to enhance the precision of radiotherapy by adapting to daily deformations in the thorax, which can occur due to factors like breathing and organ filling. Patients will undergo a cone-beam CT scan at the start of each treatment to assess tumor extent and make necessary adjustments to the radiation dose distribution. The goal is to improve treatment outcomes by ensuring that the radiation is accurately targeted to the tumor while minimizing exposure to surrounding healthy tissues.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) at stage III or IV who are eligible for neoadjuvant or definitive radiotherapy.
Not a fit: Patients who are unable to perform a reproducible breath-hold maneuver during treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment for lung cancer patients, potentially improving survival rates and reducing side effects.
How similar studies have performed: Other studies have shown promise with adaptive radiotherapy approaches, indicating potential for success in this novel application for lung cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with NSCLC/SCLC ≥18 years of age in stage III or IV, oligometastatic, for whom the indication for neoadjuvant or definitive radiotherapy/radiotherapy/chemotherapy has been established in the certified lung tumour board. Exclusion Criteria: * Patients who are unable to perform a reproducible breath-hold manoeuvre on inspiration are not included in this study.
Where this trial is running
Essen, NRW
- Klinik für Strahlentherapie, Universitätsklinikum Essen — Essen, NRW, Germany (RECRUITING)
Study contacts
- Study coordinator: Christoph Pöttgen, MD
- Email: christoph.poettgen@uk-essen.de
- Phone: +49 201 723
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer